Rodent hepadnavirus cores with reduced carrier-specific antigenicity
AssigneeVLP Biotech, Inc.
InventorsDavid R. MILICH, David C. WHITACRE
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to hepadnavirus core antigens in which one or more endogenous b cell epitopes have been effectively removed. More specifically, the present disclosure relates to rodent hepadnavirus cores modified to diminish the antibody response to the core so as to enhance the antibody response to heterologous polypeptides included therein.
Claims5
An antigenic composition comprising a hybrid rodent hepadnavirus core antigen, wherein the hybrid core antigen is a fusion protein comprising a heterologous antigen and a rodent hepadnavirus core antigen with reduced antigenicity, and wherein said fusion protein is capable of assembling as a hybrid virus-like particle (VLP).
Dependencies are inferred from the claim text.